Chief Executive Officer Makatsaria Vladimir converted options into 9,330 units of Ordinary Shares and covered exercise/tax liability with 5,046 units of Ordinary Shares (SEC Form 4)
$LIVN
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
LivaNova PLC [ LIVN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 03/30/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Ordinary Shares | 03/30/2025 | M | 9,330 | A | $0 | 9,330(1) | D | |||
| Ordinary Shares | 03/30/2025 | F | 5,046(2) | D | $39.13 | 4,284 | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Restricted Stock Units | (3) | 03/30/2025 | M | 3,352 | (4) | (4) | Ordinary Shares | 3,352 | $0 | 10,055 | D | ||||
| Restricted Stock Units | (3) | 03/30/2025 | M | 5,978 | (4) | (4) | Ordinary Shares | 5,978 | $0 | 17,931 | D | ||||
| Restricted Stock Units | (3) | 03/30/2025 | A | 35,139 | (5) | (5) | Ordinary Shares | 35,139 | $0 | 35,139 | D | ||||
| Performance Stock Units | (6) | 03/30/2025 | A | 17,569 | (7) | (7) | Ordinary Shares | 17,569 | $0 | 17,569 | D | ||||
| Performance Stock Units | (6) | 03/30/2025 | A | 17,569 | (8) | (8) | Ordinary Shares | 17,569 | $0 | 17,569 | D | ||||
| Performance Stock Units | (6) | 03/30/2025 | A | 35,139 | (9) | (9) | Ordinary Shares | 35,139 | $0 | 35,139 | D | ||||
| Stock Appreciation Rights | $39.13 | 03/30/2025 | A | 76,927 | (10) | 03/30/2035 | Ordinary Shares | 76,927 | $0 | 76,927 | D | ||||
| Explanation of Responses: |
| 1. Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. |
| 2. Shares withheld to satisfy tax liability. |
| 3. Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the Plan) and the award agreement. |
| 4. On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. |
| 5. On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. |
| 6. Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Plan and the award agreement. |
| 7. On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's free cash flow (FCF) for performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
| 8. On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's Return on Investment Capital (ROIC) calculated for the performance period 2025-2027 compares to a target determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
| 9. On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
| 10. On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. |
| Remarks: |
| /s/ Sarah K. Mohr, Attorney-in-Fact | 04/01/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||